News

Around 84 subjects with late-prodromal or early-manifest HD will be included in the Phase III SIGNAL trial. The trial will be performed with the assistance of the Huntington

In the trial, patients received 12 weeks of Viekirax+ Exviera without ribavirin (RBV) and the results showed 100% sustained virologic response at 12 weeks post-treatment (SVR12) in these

CDC’s Advisory Committee recommend that decisions to vaccinate adolescents and young adults of this age group against serogroup B meningococcal (MenB) disease should be made at the individual

The results showed that CPX-351 produced a relative improvement in induction response rate of 43.2% (47.7% for CPX-351 vs. 33.3% for the 7+3 regimen). Data on overall survival,

The agreement funds ongoing retrospective research already underway. The two institutions are also discussing the formation of the New York State Medical Marijuana Research Network (MMRN), which will

The Japanese pioneer in biotherapeutics is leveraging the Medidata Clinical Cloud to support research on a therapy for the treatment of Fabry disease, bringing greater speed and operational

"We are very pleased to announce the enrolment of the first patient in this important and second indication for our lead product. This is another important milestone for

In preclinical studies, AG-881 was shown to fully penetrate the blood-brain barrier and inhibit IDH1 and IDH2 mutations in cancer models. IDH1 and IDH2 are two metabolic enzymes

According to Fenix Leung, DPhil, GlobalData’s Analyst covering Oncology and Hematology, data from BMS’ Phase III trial, CheckMate-067, which compared the combination of the Opdivo (nivolumab) and Yervoy